Melanoma Associated Retinopathy MAR Panel by Immunoblot and IHC
Use
The Melanoma Associated Retinopathy (MAR) Panel is used for the detection of antibodies associated with melanoma-induced paraneoplastic retinopathy. This panel utilizes immunoblot and immunohistochemistry methods to detect MAR antibodies, aiding in the diagnosis and management of conditions related to this specific autoimmune retinopathy. It plays a significant role in the clinical assessment for patients with visual symptoms potentially linked to melanoma.
Special Instructions
Submit one of the following specimens with the required documentation: Serum or Plasma. Ensure that the OHSU Ocular request form, complete clinical history, and referring physician information are included. Testing cannot proceed without these documents. Note that the test is orderable for NY State clients.
Limitations
Limitations of this test may include variability in antibody levels that could affect detection sensitivity. The test may not detect all antibodies associated with MAR, and false negatives or positives could occur. Factors such as specimen quality and handling are critical to the accuracy of the results. Hemolysis and certain temperatures during transport can also affect the integrity of the sample.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
16-35 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
5 mL
Minimum Volume
3 mL
Container
Plastic vial
Collection Instructions
Draw blood in a plain, red-top tube or serum gel tube. Spin down and send serum refrigerated.
Causes for Rejection
Mild hemolysis acceptable; gross hemolysis reject. Warm reject; cold OK for thawing.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |